Efficacy of Ramelteon in pharmacoresistant patients with Dravet syndrome aged more than 6 years in the pediatric epileptic centers in seizures control
Not Applicable
Recruiting
- Conditions
- Dravet Syndrome.Polymorphic epilepsy in infancy (PMEI)G40.83
- Registration Number
- IRCT20220105053639N1
- Lead Sponsor
- Theracule AS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Minimum seizure frequency should be 6 seizures per month
Minimum age should be 6 years old
Exclusion Criteria
If the patient can not swallow the tablet.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Seizure frequency. Timepoint: Measurement of seizure frequency one month before the study (before the intervention) and 1, 2 and 3 months after the start of Remeltion treatment. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method Any outcome other than reducing the frequency of seizures and improving the quality of treatment (side effect) is considered a secondary consequence. Timepoint: Measurement of seizure frequency one month before the study (before the intervention) and 1, 2 and 3 months after the start of Remeltion. Method of measurement: Questionnaire.